Sareena Rana

This study links oncogenic RAS activity to immune priming and adenosine-driven immune evasion in lung adenocarcinoma, showing both pro-immunogenic and immunosuppressive effects.

This study shows that targeting drug-sensitive cancer cells with G12Ci inhibitors and combining it with immune therapies can eliminate drug-resistant subclones through immune-mediated bystander killing.

The paper develops covalent inhibitors targeting the RAS binding domain of PI3Kα, showing efficacy against RAS and HER2-driven tumors without affecting glucose homeostasis.

The paper identifies regulatory T cells as mediators of resistance to KRAS-G12C inhibitors and anti-PD-1 therapy through spatial proteomic analysis of lung cancer models.

This paper shows that combining RASG12C(ON) and SHP2 inhibitors can make cold lung tumors responsive to immune checkpoint blockade by altering the tumor microenvironment and enhancing anti-tumor immunity.